DISCO App: A patient intervention to reduce the financial burden of cancer in a diverse patient population.

• DOI: 10.1200/jco.2025.43.16_suppl.tps1659
• Publication Date: 2025-05-28T16:43:03Z
• Authors: Lauren M. Hamel; David W. Dougherty; Seongho Kim; Elisabeth I. Heath; Lorna Mabunda; Teneisha Austin; Hadeel Assad; Hirva Mamdani; Eyouab Tadesse; Roman Grossi; Nouran Jarbo; Susan Eggly

TPS1659

Background: Financial toxicity, the material and psychological burden of treatment cost, affects up to half of people with cancer and can affect adherence and survival. Financial toxicity is a health equity issue, disproportionately affecting Black patients. Patient education about cost and patient-provider cost discussions are recommended to mitigate financial toxicity but occur infrequently. Our goal is to mitigate financial toxicity through a tailorable education and communication intervention, the DISCO App. The DISCO App was shown to be feasible, acceptable, and preliminarily effective at prompting cost discussions and improving related outcomes in a pilot trial. The aim of the ongoing trial is to test the effectiveness of the DISCO App on short- and longer-term outcomes for Black and White patients with cancer. Methods: This study is a longitudinal RCT. Oncologists are eligible if they treat patients with solid tumors at the trial site. Patients of participating oncologists are eligible if they are ≥ 18 years of age; identify as Black or White; can read and write in English; have an email address; and were diagnosed with a solid tumor for which systemic therapy is a likely recommended treatment. Strata were created to balance arms by patient race, income, age, and sex. Upon consent, patients are randomized to one usual care arm (1) or one of two intervention arms (2 and 3). All patients are asked to allow one treatment discussion with their oncologist to be video recorded for analysis. Prior to the recording, intervention patients utilize the DISCO App on an iPad. The DISCO App includes a video about treatment costs, ways to manage costs, and the importance of discussing costs with oncologists. Once patients enter their socio-demographic information (e.g., employment, insurance) and any financial concerns, they receive a tailored list of questions to ask their oncologist. Arm 3 patients receive an intervention booster via email two months after the recording. Patients complete measures at baseline, right after the recording, and at 1, 3, 6 and 12 months after the recording. Measures assess outcomes including cost discussions, communication quality, cost knowledge, self-efficacy for cost management, referrals for support, short- and longer-term financial toxicity, and treatment adherence. The patient-oncologist interaction is the unit of analysis and we will use multi-linear models to compare outcomes by arm. We anticipate recruiting up to 15 oncologists and 240 patients. Data collection began in March 2021 and will continue until July 2025. Participants to date include 13 oncologists and 192 patients (116 Black, 76 White). Most patients completed the baseline assessment (n=164), the post-interaction assessment (n=137), and at least 1 follow-up assessment (n=132); 125 treatment discussions have been recorded. The IRB reviewed the trial in December 2024 and approved continuation.

Clinical trial information: NCT04766190

.